Literature DB >> 18254150

Determination of levonorgestrel in human plasma by liquid chromatography-tandem mass spectrometry method: application to a bioequivalence study of two formulations in healthy volunteers.

Li-Zi Zhao1, Guo-Ping Zhong, Hui-Chang Bi, Liang Ding, Ying Deng, Su Guan, Xiao Chen, Zhi-ying Huang, Min Huang.   

Abstract

A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to determine levonorgestrel in human plasma was developed and fully validated. After hexane-ethyl acetate (70:30, v/v) induced extraction from the plasma samples, levonorgestrel was subjected to LC/MS/MS analysis using electro-spray ionization. The MS system was operated in the selected reaction monitoring mode. Chromatographic separation was performed on a Hypersil BDS C18 column (i.d. 2.1x50 mm, particle size 3 microm). The method had a chromatographic running time of 2.0 min and linear calibration curves over the concentration ranges of 0.25-90 ng/mL for levonorgestrel. The lower limit of quantification of the method was 0.25 ng/mL for levonorgestrel. The intra- and inter-batch precision was 3.7-10.2 and 5.1-12.9%, respectively, for all quality control samples at concentrations of 0.5, 6.0 and 45.0 ng/mL. These results indicate that the method was efficient with a simple preparation procedure and a very short running time (2.0 min) for levonorgestrel compared with those methods reported in the literature and had high selectivity, acceptable accuracy, precision and sensitivity. The validated LC/MS/MS method was successfully used for a bioequivalence study of two tablet formulations of levonorgestrel in healthy volunteers. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18254150     DOI: 10.1002/bmc.963

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  5 in total

1.  Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

Authors:  Lauren R Cirrincione; Sujan Dilly Penchala; Kimberly K Scarsi; Anthony T Podany; Lee C Winchester; David J Back; Saye H Khoo; Courtney V Fletcher; Marco Siccardi; Laura J Else
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-12       Impact factor: 3.205

2.  Efficacy and safety of a levonorgestrel enteric-coated tablet as an over-the-counter drug for emergency contraception: a Phase IV clinical trial.

Authors:  Q-J Chen; W-P Xiang; D-K Zhang; R-P Wang; Y-F Luo; J-Z Kang; L-N Cheng
Journal:  Hum Reprod       Date:  2011-06-13       Impact factor: 6.918

3.  High-sensitivity simultaneous liquid chromatography-tandem mass spectrometry assay of ethinyl estradiol and levonorgestrel in human plasma.

Authors:  Abhishek Gandhi; Swati Guttikar; Priti Trivedi
Journal:  J Pharm Anal       Date:  2015-02-20

4.  Comparison of ESI- and APCI-LC-MS/MS methods: A case study of levonorgestrel in human plasma.

Authors:  Rulin Wang; Lin Zhang; Zunjian Zhang; Yuan Tian
Journal:  J Pharm Anal       Date:  2016-03-29

5.  Models and methods to characterise levonorgestrel release from intradermally administered contraceptives.

Authors:  Adnan Al Dalaty; Benedetta Gualeni; Sion A Coulman; James C Birchall
Journal:  Drug Deliv Transl Res       Date:  2021-12-03       Impact factor: 4.617

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.